The CF Foundation is committed to bringing the best scientific minds and technology into our mission to cure CF and help all people with the disease live long, fulfilling lives. More than 20 years ago, the organization pioneered a model for collaborative drug discovery and development that is now known as venture philanthropy. Our approach is to provide upfront research funding, as well as scientific and clinical expertise, to reduce the technical and financial risk for pharmaceutical companies developing innovative CF therapies and encourage them to invest in treatments and cures for CF. In some cases, the CF Foundation may also receive the right to milestone-based payments, equity interests, royalties on the net sales of therapies, and/or other forms of consideration in return for our CF research funding. This provides a potential financial return which helps advance our mission, including funding new research to discover and develop drugs that will help more people with CF. Nearly every CF drug available today was made possible because of our model.
The most significant of those investments was research funding to Aurora Biosciences (now Vertex Pharmaceuticals, Inc.) to identify and develop treatments for the underlying cause of CF. Those investments resulted in multiple transformative therapies to treat CF and the sale of royalty rights related to those medicines to Royalty Pharma for $3.3 billion in 2014. Under terms of the agreement with Royalty Pharma, the CF Foundation maintained a stake in future royalties. On October 30, 2020, we sold our remaining stake in royalties from Vertex CFTR modulators to Royalty Pharma for an upfront payment of $575 million. Under the terms of the agreement, the CF Foundation may also receive a potential future payment of $75 million from Royalty Pharma; that payment is not tied to product sales.
Since the sale of royalty rights in 2014, we have supercharged our mission, investing in CF research, care, and community programs at an unprecedented rate. We are investing in virtually every aspect of CF including a $500 million Path to a Cure initiative to accelerate progress towards treatments for everyone with CF; helping to address challenges that people with CF continue to face today with a $100 million Infection Research Initiative, a $40 million Lung Transplant Initiative, and a significant focus on complications. Following the sale, we also established a Community Partnerships function to provide educational and support programming, as well as listening efforts and mentoring, particularly for the growing adult population; and broadened community support through our Compass assistance program, which fields an average of 11,000 calls from CF patients and families every year.